More than fifty years after the Biological Weapons Convention entered into force, the treaty still lacks a standing system for verifying compliance amid rapid technological advancements and geopolitical mistrust. Because dual-use biotechnology encompasses digital genetic sequences, automation, and distributed manufacturing alongside physical pathogens, compliance depends on contextual interpretation rather than simple warhead counting.
To overcome the collapse of the 2001 verification protocol negotiations, member states should consider incorporating professional independent "bioaudits" into a layered international verification framework. Modeled on corporate financial audits, accredited third parties could scrutinize laboratories and biotechnology companies for operational compliance and biosecurity governance. While an individual audit cannot detect clandestine programs or prove total state compliance, structured bioaudits can substantiate national declarations, establish common international standards, and generate reliable evidence to replace unverified national assurances.
Financial-style audit frameworks alter the verification baseline by shifting oversight from declared state intent to institutional operational integrity. When applied to dual-use infrastructure under the Biological Weapons Convention, third-party assessments create a verifiable audit trail that is harder to dismiss than unilateral declarations. However, unlike traditional arms control regimes governed by physical asset verification, modern biotechnology relies on distributed data and synthetic biology that resist standard inspection protocols.
No comments:
Post a Comment